EICHORCondition: Immune-Mediated Cholestasis · Sponsor: University Hospital, Montpellier
The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period. The trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.
This description comes directly from the study's public registry record.
Dr. MEUNIER · +33467330224 · lucy.meunier@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| CHU Bordeaux | Bordeaux, France | — |
| HCL Croix Rousse | Lyon, France | — |
| CHU Montpellier | Montpellier, France | — |
| APHP Paul Brousse | Paris, France | — |
| CHU Poitiers | Poitiers, France | — |
| CHU Toulouse | Toulouse, France | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07378761